Clinical Trials for Hypomagnesaemia
Currently, there is one ongoing clinical trial investigating treatment options for hypomagnesaemia, specifically focusing on patients with low magnesium levels caused by HNF1beta-associated kidney disease. This trial is examining whether the medication dapagliflozin can help improve blood magnesium levels in affected individuals.
Clinical trial locations
Study on the Effect of Dapagliflozin on Blood Magnesium Levels in Patients with Low Magnesium Due to HNF1beta-Associated Kidney Disease
This clinical trial is investigating how the medication dapagliflozin affects blood magnesium levels in patients who have low magnesium due to a genetic kidney condition caused by a mutation in the HNF1beta gene. This condition results in the kidneys losing too much magnesium through urine, which can lead to symptoms like muscle cramps, weakness, and fatigue.
Main inclusion criteria:
- Must have genetically confirmed HNF1beta disease
- Must have low blood magnesium levels (below 0.70 mmol/l)
- Must be between 18 and 75 years of age
- Must provide informed consent to participate
Main exclusion criteria:
- Known allergy to the study medication or its ingredients
- Currently participating in another clinical trial
- Severe kidney disease
- Pregnancy or breastfeeding
- History of certain heart conditions, such as heart failure
- Uncontrolled diabetes with unstable blood sugar levels
- History of alcohol or drug abuse
- Certain liver diseases
- Recent major surgery
- Any other medical condition that study doctors believe would make participation unsafe
Focus and goal: The main purpose of this trial is to evaluate whether dapagliflozin can help improve magnesium levels in the blood of patients with HNF1beta-associated kidney disease. Participants will receive either dapagliflozin (10 mg once daily) or a placebo in tablet form for a treatment period of four weeks. Throughout the study, blood magnesium levels and other health parameters will be monitored regularly to assess any changes. The trial aims to provide valuable insights that could lead to better treatment options for individuals with this rare genetic condition, which can affect both diabetic and non-diabetic patients.
Investigational drug: Dapagliflozin is the medication being tested in this trial. It is typically used to manage blood sugar levels in people with type 2 diabetes by blocking a protein called SGLT2 in the kidneys, which increases the removal of glucose through urine. In this study, researchers want to understand how this mechanism might also influence magnesium levels in patients with HNF1beta mutations.
Summary
Currently, there is only one ongoing clinical trial for hypomagnesaemia, specifically targeting patients with a genetic form of the condition caused by HNF1beta mutations. This trial is being conducted in the Netherlands and focuses on evaluating the medication dapagliflozin, which is already established for diabetes treatment but is now being explored for its potential to improve magnesium levels in this specific patient population. The study is expected to conclude by July 2025 and represents an important step in understanding treatment possibilities for this rare genetic kidney condition.
